Featured
-
Featured
Clinical trials are the single biggest operational and financial risk for small to mid-size biotech companies. Fifty to eighty percent of trials miss enrollment targets, unplanned amendments cost $150-300K each, and database lock delays push readouts back months. For companies with just 18-24 months of runway, every setback erodes investor confidence, delays financing, and gives […]
Free